BeOne Medicines (HKSE:06160) Effective Interest Rate on Debt % : 0.00% (As of Mar. 2025)

View and export this data going back to 2018. Start your Free Trial

What is BeOne Medicines Effective Interest Rate on Debt %?

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. BeOne Medicines's annualized positive value of Interest Expense for the quarter that ended in Mar. 2025 was HK$0 Mil. BeOne Medicines's average total debt for the quarter that ended in Mar. 2025 was HK$8,071 Mil. Therefore, BeOne Medicines's annualized Effective Interest Rate on Debt % for the quarter that ended in Mar. 2025 was 0.00%.

BeOne Medicines Effective Interest Rate on Debt % Historical Data

The historical data trend for BeOne Medicines's Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BeOne Medicines Effective Interest Rate on Debt % Chart

BeOne Medicines Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Effective Interest Rate on Debt %

Get a 7-Day Free Trial

2.51

BeOne Medicines Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Effective Interest Rate on Debt %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of BeOne Medicines's Effective Interest Rate on Debt %

For the Biotechnology subindustry, BeOne Medicines's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BeOne Medicines's Effective Interest Rate on Debt % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BeOne Medicines's Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where BeOne Medicines's Effective Interest Rate on Debt % falls into.

Save Embed

;

Save Embed

;

BeOne Medicines Effective Interest Rate on Debt % Calculation

BeOne Medicines's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Dec. 2024 is calculated as

	Effective Interest Rate on Debt %
=	-1 * Interest Expense	/	( (Total Debt (A: Dec. 2023 )	+	Total Debt (A: Dec. 2024 ))	/ count )
=	-1 * 0	/	( (7264.559	+	8394.231)	/ 2 )
=	-1 * 0	/	7829.395
=	0.00 %

where

	Total Debt (A: Dec. 2023 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	1717.133	+	5547.426
=	7264.559

	Total Debt (A: Dec. 2024 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	1638.33	+	6755.901
=	8394.231

BeOne Medicines's annualized Effective Interest Rate on Debt % for the quarter that ended in Mar. 2025 is calculated as

	Effective Interest Rate on Debt %
=	-1 * Interest Expense	/	( (Total Debt (Q: Dec. 2024 )	+	Total Debt (Q: Mar. 2025 ))	/ count )
=	-1 * 0	/	( (8394.231	+	7748.121)	/ 2 )
=	-1 * 0	/	8071.176
=	0.00 %

where

	Total Debt (Q: Dec. 2024 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	1638.33	+	6755.901
=	8394.231

	Total Debt (Q: Mar. 2025 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	1671.556	+	6076.565
=	7748.121

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is four times the quarterly (Mar. 2025) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.

BeOne Medicines (HKSE:06160) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.

BeOne Medicines Effective Interest Rate on Debt % Related Terms

Thank you for viewing the detailed overview of BeOne Medicines's Effective Interest Rate on Debt % provided by GuruFocus.com. Please click on the following links to see related term pages.

BeOne Medicines Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BeOne Medicines Ltd (HKSE:06160) » Definitions » Effective Interest Rate on Debt %

Comparable Companies

Traded in Other Exchanges

BEIGF:USA ONC:USA 49B:Germany 688235:China B1ME34:Brazil

Address

c/o BeOne Medicines I GmbH, Aeschengraben 27, 21st Floor, Basel, CHE, 4051

Website

https://www.beonemedicines.com

Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene's revenue.

Executives

Baker Felix James	2201 Interest of corporation controlled by you
Baker Julian Charles	2201 Interest of corporation controlled by you
Baker Bros. Advisors (gp) Llc	2201 Interest of corporation controlled by you
Baker Brothers Life Sciences Capital, L.p.	2201 Interest of corporation controlled by you
Jpmorgan Chase & Co.	2502 Approved lending agent
Oyler John Victor	2101 Beneficial owner
The Capital Group Companies, Inc.	2201 Interest of corporation controlled by you
Hhlr Advisors, Ltd.	2102 Investment manager
Hhlr Fund, L.p.	2101 Beneficial owner
Amgen Inc.	2101 Beneficial owner
Hillhouse Capital Advisors, Ltd.	2102 Investment manager
Gaoling Fund, L.p.	2101 Beneficial owner
Fidelity Management & Research Company
Fmr Co., Inc.

BeOne Medicines Headlines

No Headlines